FIELD: medicine.
SUBSTANCE: pharmaceutical composition as a medical product includes low-sialyl forms of erythropoetin with the content of 6-8 remainders of sialine acids per protein molecule. The invention provides expansion of an arsenal of effective medical products for treatment of neurologic diseases.
EFFECT: expansion of an arsenal of effective medical products for treatment of neurologic diseases.
3 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOMODELLING PREPARATION FOR INJECTION-FREE APPLICATION | 2001 |
|
RU2197986C2 |
| PROCESS FOR PRODUCING POLYMER NANOPARTICLES OF LOW-SIALYLATED ERYTHROPOETIN WITH HIGH SORPTION DEGREE FOR TREATMENT OF NEUROLOGICAL DISEASES | 2014 |
|
RU2616258C2 |
| METHOD FOR ASSESSMENT OF NEUROTROPHIN GENES EXPRESSION | 2009 |
|
RU2383619C1 |
| METHOD OF SCREENING PHARMACOLOGICAL COMPOUNDS ACCORDING TO NEUROPROTECTIVE ACTIVITY | 2009 |
|
RU2383615C1 |
| STABILIZED ERYTHROPOIETIN AQUEOUS SOLUTION | 1998 |
|
RU2128517C1 |
| STRAIN OF CHINESE HAMSTER OVARY CELLS CHO-EPO 4A9 - PRODUCER OF HIGHLY SIALYLATED ERYTHROPOETHIN | 2016 |
|
RU2652884C1 |
| METHOD OF PRODUCING MAMMAL EMBRYONIC STEM CELLS MODIFIED WITH HUMAN NERVE GROWTH FACTOR GENE | 2011 |
|
RU2458984C1 |
| ARTIFICIAL PEPTIDE FOR CRANIOCEREBRAL INJURY TREATMENT | 2023 |
|
RU2816919C1 |
| PHARMACEUTICAL COMPOSITION WITH CYTOKINE AND IMMUNOMODULATING EFFECTS | 2002 |
|
RU2222345C2 |
| METHOD OF OBTAINING CONDITIONED MEDIA WITH REGENERATIVE POTENTIAL FOR INTRANASAL INTRODUCTION IN TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2637407C1 |
